The AVATAR trial, a phase II clinical trial, included patients with hereditary leiomyomatosis and papillary RCC, a familial cancer syndrome caused by an enzyme FH mutation, versus patients with sporadic papillary RCC and at most two previous treatments with VEGFR inhibitor agents (Srinivasan et al. 2020). The gene discussed is FH; the disease is hereditary leiomyomatosis and renal cell cancer.